Eli Lilly, Adaptimmune, Aurion Biotech, and ImmunityBio had breakthrough medicines and therapies debut in the past year.

It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug ...

Eli Lilly has chalked up another regulatory approval for its anti-amyloid therapy for Alzheimer's disease, Kisunla, in China – the world's second-largest pharma market. The National Medical ...

Eli Lilly says a new starting dose regimen for its Alzheimer's disease therapy Kisunla reduces the risk of side effects that have stood in the way of approvals and reimbursement decisions for ...

Eli Lilly (NYSE: LLY) has been around for almost 150 years, finding ways to innovate and grow. Today, it's the most valuable ...

First, let's consider how Eli Lilly's newest products will affect its performance in the next half-decade. These new medicines include Alzheimer's disease treatment Kisunla, ulcerative colitis ...

Perhaps Eli Lilly's most promising recent approval is Kisunla, an Alzheimer's disease treatment. Despite an aging population, few medicines in this field have earned the green light from ...

Furthermore, rapidly growing products such as Mounjaro, Zepbound, Verzenio, Ebglyss, and Kisunla, are expected to sustain strong growth. The firm expects Eli Lilly and Company (NYSE:LLY ...

Eli Lilly (NYSE: LLY) has been around for almost ... However, there's also hope that Alzheimer's drug Kisunla, which regulators approved last year, may also become a blockbuster for the business.